Triplet Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company leveraging human genetics to develop treatments for repeat expansion disorders at their source, raised $59m in financing.

This includes a $49m Series A financing led by MPM Capital and Pfizer Ventures U.S. LLC, the venture capital arm of Pfizer Inc. (NYSE: PFE).

Atlas Venture, which co-founded and seeded Triplet with a $10m investment, also participated in the Series A alongside Invus, Partners Innovation Fund and Alexandria Venture Investments.

By precisely reducing activity of select DDR targets, the company’s approach is designed to halt onset and progression across a wide range of repeat expansion disorders.

The company’s senior management includes:Nessan Bermingham, Ph.D., co-founder, president and chief executive officer,Irina Antonijevic, M.D., Ph.D., senior vice president of development,Brian Bettencourt, Ph.D., senior vice president of computational biology & statistics,David Morrissey, Ph.D., senior vice president of technology,Eric Sullivan, CPA, chief financial officer, and JeffreyM. Cerio, Pharm.D., J.D., senior vice president & general counsel. | To read full story, visit https://startuparound.com/read/1576584008.632858/Triplet-Therapeutics-Raises-$59M-in-Financing?ref=audio_experience